首页> 美国卫生研究院文献>other >Clinicopathologic Features of Late Onset Veno-Occlusive Disease/Sinusoidal Obstructive Syndrome After High Dose Busulfan and Hematopoietic Cell Transplantation
【2h】

Clinicopathologic Features of Late Onset Veno-Occlusive Disease/Sinusoidal Obstructive Syndrome After High Dose Busulfan and Hematopoietic Cell Transplantation

机译:高剂量套管和造血细胞移植后晚期发作静脉闭塞性疾病/正弦阻塞性综合征的临床病理特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Most cases of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) occur <21 days after allogeneic hematopoetic stem cell transplantation (HCT). Rarely, however, VOD/SOS can occur later, and can be confused with other causes. We report the clinicopathologic features of 8 patients with advanced hematologic malignancies developing VOD/SOS >30 days after dose-escalated busulfan/fludarabine/alemtuzumab and HCT. Median time to diagnosis=52 days (range: 33–77). For 7 patients, VOD/SOS was confirmed by liver biopsies showing classical features including reticulin deposition within sinusoids, central vein occlusions, hepatocyte atrophyecrosis, sinusoidal/perivenular hemorrhage, and sparing of portal tracts. VOD/SOS risk was directly related to higher busulfan plasma exposures. Two patients died from VOD/SOS, and in another two patients VOD/SOS was contributory to death. Late-onset VOD/SOS may be underrecognized and should be considered in the differential diagnosis of patients undergoing HCT, particularly after high dose busulfan. Liver biopsy should be entertained even late in the course if appropriate signs/symptoms exist.
机译:大多数静脉内疾病/正弦梗阻综合征(VOD / SOS)的病例发生了<同种异体造血干细胞移植(HCT)后发生<21天。然而,很少,稍后可以发生VOD / SOS,并且可以与其他原因混淆。我们报告了8例患有晚期血液学恶性肿瘤患者的临床病理特征,在剂量升级的Busulfan / Fludarabine / Alemtuzumab和HCT后30天开发vod / sos> 30天。中位时间诊断= 52天(范围:33-77)。对于7名患者,通过肝脏活组织检查证实VOD / SOS显示出古典特征,包括在正弦曲线中,中央静脉闭塞,肝细胞萎缩/坏死,正弦/静脉出血和门骨紊乱中的网状蛋白沉积。 VOD / SOS风险与较高的Busulfan等离子体曝光直接相关。两名患者从VOD / SOS中死亡,另外两名患者在vod / sos中有助于死亡。后期vod / sos可能会被遗憾地识别,并且应该在接受HCT患者的差异诊断中考虑,特别是在高剂量的Busulfan之后。如果存在适当的迹象/症状,肝脏活组织检查甚至应该在课程中晚期娱乐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号